Aster Capital Management DIFC Ltd Makes New Investment in iShares Biotechnology ETF $IBB

Aster Capital Management DIFC Ltd bought a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,210 shares of the financial services provider’s stock, valued at approximately $1,907,000. iShares Biotechnology ETF comprises about 1.0% of Aster Capital Management DIFC Ltd’s portfolio, making the stock its 14th largest position.

A number of other large investors also recently modified their holdings of IBB. Citigroup Inc. increased its holdings in shares of iShares Biotechnology ETF by 27.0% in the second quarter. Citigroup Inc. now owns 4,073,967 shares of the financial services provider’s stock valued at $515,398,000 after purchasing an additional 865,823 shares in the last quarter. JPMorgan Chase & Co. boosted its position in iShares Biotechnology ETF by 74.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 833,196 shares of the financial services provider’s stock valued at $105,408,000 after buying an additional 355,000 shares during the last quarter. Employees Retirement System of Texas acquired a new stake in shares of iShares Biotechnology ETF in the 2nd quarter valued at $25,049,000. Millennium Management LLC increased its stake in shares of iShares Biotechnology ETF by 140.8% in the 1st quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock valued at $5,330,000 after buying an additional 143,893 shares during the period. Finally, Florin Court Capital LLP bought a new stake in shares of iShares Biotechnology ETF during the third quarter worth $11,116,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Down 0.8%

Shares of IBB opened at $173.88 on Friday. The stock’s fifty day simple moving average is $172.77 and its 200-day simple moving average is $159.84. iShares Biotechnology ETF has a 12-month low of $107.43 and a 12-month high of $179.64.

iShares Biotechnology ETF Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, December 19th. Stockholders of record on Tuesday, December 16th were paid a $0.1831 dividend. This is a boost from iShares Biotechnology ETF’s previous quarterly dividend of $0.08. The ex-dividend date of this dividend was Tuesday, December 16th. This represents a $0.73 annualized dividend and a dividend yield of 0.4%.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.